Below are the NCI Cooperative Group active protocol list within the HCC Clinical Trials Network program. If you wish to access the cooperative group protocol documents and updates, please use the cooperative group links below. Protocol documents are available to cooperative group members who have an active username and password. If you are having difficulty accessing a protocol document, contact your research coordinator or the Network office.

 

Disease Site	Coop Protocol Number	Protocol Title	CTN Member
Breast	NSABP B-39/ RTOG 0413	A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0,I, or II Breast Cancer	Georgetown Hospital System PI: Eric Aguero, MD   Carolina Regional Cancer Center PI: Todd Williams, MD
Breast	SWOG 0226	Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post-Menopausal Women with Metastatic Breast Cancer	The Regional Medical Center of Orangeburg and Calhoun Counties PI: Chris Y. Brunson, MD
Genitourinary	RTOG 0415	A Phase II Randomized Study of Hypofractionated 3-D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer	Carolina Regional Cancer Center PI: Todd Williams, MD
Breast	NSAPB B-40	A Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect in Pathologic Complete Response (pCD) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimes	Georgetown Hospital System PI: Darren Mullins, MD
Breast	Tailor-X PACCT-1	Program for the Assistance of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The Tailor-X Trial	Georgetown Hospital System PI: Darren Mullins, MD
Gastrointestinal	CALGB C80405	A Phase II Trial of Irinotecan, 5FU, Leucovorin or Oxaliplatin, 5FU, Leucovorin with Bevacizumab or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Color or Rectum	Georgetown Hospital System PI: Darren Mullins, MD
Gastrointestinal	ECOG 5202	A Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin Vs. 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer at High Risk to Determine Prospectively to Prognostic value of Molecular Markers	Georgetown Hospital System PI: Darren Mullins, MD
Gastrointestinal	ECOG 5204	Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin Vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pro-operative Chemoradiation.	Georgetown Hospital System PI: Darren Mullins, MD